000			01954nam a2200277Ia 4500
008			230724s2002 xx 000 0 und d
040			_cManila Tytana Colleges
100			_aAliot, E. _97823
245		0	_aVentricular instability and sudden death in patients with heart failure : _blessons from clinical trials / _cE. Aliot, C. de Chillou, N. Sadoul
260			_cApril 2002
336			_atext
337			_aunmediated
338			_avolume
440			_n4 : Supplement D, pages D31-D42 _aEuropean Heart Journal Supplements _97824
520			_aVarious trials using non-antiarrhythmic drugs, antiarrhythmic agents and implantable-cardioverter defibrillators (ICDs) have been performed in order to decrease the incidence of sudden death and to improve survival in chronic heart failure (CHF). The present review addresses some of the key findings of those trials. First, it addresses the importance of considering the potential electrophysiological effects of non-antiarrhythmic drugs and of using angiotensin-converting enzyme inhibitors, beta-blockers and antialdosterone agents in the optimal management of patients with CHF. Second, it reviews the effects of the antiarrhythmic agent amiodarone on mortality and arrhythmic deaths in patients with depressed left ventricular function. Third, it assesses the evidence that patients with CHF and a history of sustained ventricular arrhythmias or resuscitation may benefit from ICD implantation. Finally, it outlines the growing role of ICD therapy in patients with CHF as a primary indication.
521			_aNursing.
650			_aAmiodarone. _97825
650			_aAngiotensin-converting enzyme inhibitors. _97826
650			_aAntiarrhythmic drugs. _97827
650			_aBeta-blockers. _97828
650			_aCongestive heart failure. _97829
650			_aImplantable cardioverter-defibrillator. _97830
650			_aSudden death. _97831
650			_aVentricular arrythmias. _97832
942			_cA
999			_c85423 _d85423